A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Read time: 1 mins
Last updated:28th Dec 2011
1) To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. 2) To assess safety and tolerability of treatment up to 5 years with odanacatib 50 mg once weekly compared to placebo.
|Study start date||2011-12-28|